166 related articles for article (PubMed ID: 20198458)
1. Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Kim YS; Park SH; Kyung SY; Sym SJ; Lee SP; Park JW; Jung SH; Park J; Cho EK; Lee JH; Shin DB
Med Oncol; 2011 Mar; 28(1):342-50. PubMed ID: 20198458
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
Horn L; Zhao Z; Sandler A; Johnson D; Shyr Y; Wolff S; Devore RF; Laskin J
Clin Lung Cancer; 2011 May; 12(3):161-5. PubMed ID: 21663858
[TBL] [Abstract][Full Text] [Related]
7. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Chen G; Huynh M; Fehrenbacher L; West H; Lara PN; Yavorkovsky LL; Russin M; Goldstein D; Gandara D; Lau D
J Clin Oncol; 2009 Mar; 27(9):1401-4. PubMed ID: 19204194
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
Sekine I; Okamoto H; Horai T; Nakagawa K; Ohmatsu H; Yokoyama A; Katakami N; Shibuya M; Saijo N; Fukuoka M
Clin Lung Cancer; 2014 Mar; 15(2):96-102. PubMed ID: 24361248
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
Kinoshita A; Fukuda M; Soda H; Nagashima S; Fukuda M; Takatani H; Kuba M; Nakamura Y; Tsurutani J; Kohno S; Oka M;
Br J Cancer; 2006 May; 94(9):1267-71. PubMed ID: 16622467
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.
Yilmaz U; Polat G; Anar C; Halilcolar H
Indian J Cancer; 2011; 48(4):454-9. PubMed ID: 22293260
[TBL] [Abstract][Full Text] [Related]
14. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
Murata Y; Hirose T; Yamaoka T; Shirai T; Okuda K; Sugiyama T; Kusumoto S; Nakashima M; Ohmori T; Adachi M
Eur J Cancer; 2011 Jun; 47(9):1336-42. PubMed ID: 21458256
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T; Okamoto H; Machida R; Misumi Y; Hosomi Y; Yoneshima Y; Tanaka H; Okishio K; Simizu J; Goto K; Akamatsu H; Kubota K; Nakagawa K; Horinouchi H; Ando M; Kataoka T; Ohe Y
Lung Cancer; 2023 Jul; 181():107195. PubMed ID: 37156212
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
18. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Kim B; Choi HC; Kwon JH; Choi DR
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1591-7. PubMed ID: 23568282
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.
Han JY; Lim KY; Yu SY; Yun T; Kim HT; Lee JS
Cancer; 2011 May; 117(10):2178-85. PubMed ID: 21523731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
